KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Royalty Pharma (RPRX) Return on Assets (2020 - 2025)

Historic Return on Assets for Royalty Pharma (RPRX) over the last 6 years, with Q3 2025 value amounting to 0.07%.

  • Royalty Pharma's Return on Assets fell 300.0% to 0.07% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.07%, marking a year-over-year decrease of 300.0%. This contributed to the annual value of 0.08% for FY2024, which is 300.0% down from last year.
  • Royalty Pharma's Return on Assets amounted to 0.07% in Q3 2025, which was down 300.0% from 0.09% recorded in Q2 2025.
  • Royalty Pharma's 5-year Return on Assets high stood at 0.12% for Q2 2021, and its period low was 0.01% during Q4 2022.
  • Over the past 5 years, Royalty Pharma's median Return on Assets value was 0.07% (recorded in 2021), while the average stood at 0.07%.
  • As far as peak fluctuations go, Royalty Pharma's Return on Assets tumbled by -800bps in 2021, and later skyrocketed by 900bps in 2023.
  • Royalty Pharma's Return on Assets (Quarter) stood at 0.07% in 2021, then plummeted by -81bps to 0.01% in 2022, then soared by 691bps to 0.11% in 2023, then crashed by -30bps to 0.07% in 2024, then fell by -6bps to 0.07% in 2025.
  • Its Return on Assets stands at 0.07% for Q3 2025, versus 0.09% for Q2 2025 and 0.1% for Q1 2025.